AZN logo
AstraZeneca PLC
AZN
70.55 (0.81%) 0.57
218.71(B)
Health Care
Pharmaceuticals
AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Crestor Seloken Lokelma Roxadustat Andexxa Wainua Symbicort Fasenra Pulmicort Breztri/Trixeo Saphnelo Tezspire Airsupra Ultomiris Soliris Strensiq Koselugo Kanuma Atacand Plendil Modip Splendil Munobal Flodil Komboglyze Qtern Byetta XIGDUO Accolate Accoleit Vanticon Beyfortus Synagis FluMist tixagevimab and cilgavimab and sipavibart. It also provides Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Bricanyl Turbuhaler Rhinocort Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Breztri Aerosphere Duaklir Genuair Kavigale Evusheld Fluenz/FluMist and Voydeya. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the United States Europe and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare life sciences and chemistry. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.
My Holdings:
(?% ownership)
Shares:
Cost basis:
Market cap:$218.71(B)
EV:$253.66(B)
Total Equity:$41.13(B)
Div. yield:2.20%
Earnings date:Jul-29-2025
P/E:28.15
P/E (fwd):15.50
P/FCF:19.62
P/S:3.98
P/B:5.33
EPS:$2.5
EPS (fwd):$4.6
FCF/share:$3.6
Dividend/share:$1.6
Book value/share:$13.2
ROIC:10.8%
ROA:7.4%
ROE:19.8%

AZN Valuation & Price Targets

  Current Price
70.55
PE Valuation
N/A
PEvaluation is not available for AZN.
Analyst targets
N/A
No analyst estimates for AZN.
DCF
N/A
Adjust your assumptions to reach a valid valuation.
DCF (exit mult.)
N/A
Adjust your assumptions to reach a valid valuation.
Future P/E
N/A
Adjust your assumptions to reach a valid valuation.
Peter Lynch FV
N/A
Adjust your assumptions to reach a valid valuation.
Graham No.
N/A
Adjust your assumptions to reach a valid valuation.
DDM
N/A
Adjust your assumptions to reach a valid valuation.

PEvaluation

35% overvalued
Low
$34.6
Mid
$46.2
High
$57.7
Current price
$70.5
Fair P/E
Margin of safety
Market Model
Shares outstan...ROICRevenue growthDebt/FCFAssets/Liabili...
Economic moat: None/narrow

Analyst Price Targets

N/A
No analyst price targets
Strong Buy5
Buy13
Hold2
Sell0
Strong Sell0

Estimated EPS

LowAvgHigh#
FY+14.24.64.918
FY+24.85.25.818
FY+35.15.86.717
FY+45.46.17.38
FY+55.66.98.26

Discounted Cash Flow

Forecast years
Terminal Growth Rate
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years
Exit FCF Multiple
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Future P/E Valuation

Projection Years
Base Revenue
Revenue Growth Rate
Final Net Margin
Final P/E Ratio
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate (*)

(*) Growth rate is capped between 0 and 25

Graham Formula

Earnings Per Share
Expected Growth Rate
Government Bond Rate

(*) Growth rate is capped to 25

Dividend Discount Model

Annual Dividend
First Stage Length (Years)
First Stage Growth Rate
Final Growth Rate
Discount Rate

(*) First stage rowth rate is capped to 20%

Based on 0 valuation methods, the average fair value estimate for AZN is $N/A (NaN% overvalued).

Valuations range from $1.7976931348623157e+308 (N/A) to $0.0 (N/A).

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$54.98(B)
Gross profit$45.33(B)
EBITDA$18.28(B)
Net income$7.77(B)
Gross margin82.4%
Operating margin19.2%
Net margin14.1%
Shares outstanding:3.10(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$106.25(B)
Current assets$26.14(B)
Total liabilities$65.12(B)
Current liabilities$29.13(B)
Cash & Short-term inv.$5.39(B)
Long-term debt$26.74(B)
Total intangibles$58.68(B)
PP&E$12.30(B)

Cash flow (TTM)

CFOCFICFF
FCF$11.15(B)
CapEx$-1.94(B)
Dividends paid$-4.94(B)
Stock issued$40.00(M)
Stock repurchased$-567.00(M)
Stock-based comp.$660.00(M)
Debt issued$1.61(B)
Debt repaid$-5.00(B)

Per share data (TTM)

Price: $70.5
Revenue: $17.7 (4.0x | 25.1%) Gross profit: $14.6 (4.8x | 20.7%) Earnings: $2.51 (28.2x | 3.6%)
FCF: $3.60 (19.6x | 5.1%) Stock-based Comp.: $0.21 (331.4x | 0.3%) Dividend: $1.55 (45.5x | 2.2%)
Total Assets: $34.3 (2.1x | 48.6%) Total Liabilities: $21.0 (3.4x | 29.8%) Book Value: $13.2 (5.3x | 18.8%) Cash & ST inv.: $1.74 (40.5x | 2.5%) Debt: $8.63 (8.2x | 12.2%)

Growth Estimates

Revenue

CAGR: 5.7%
FY+1FY+2FY+3FY+4FY+5
FY+1$57.83(B)
FY+2(+5.8%)$61.18(B)
FY+3(+5.6%)$64.58(B)
FY+4(+4.5%)$67.48(B)
FY+5(+7.0%)$72.18(B)

Net Income

CAGR: 10.9%
FY+1FY+2FY+3FY+4FY+5
FY+1$13.97(B)
FY+2(+12.9%)$15.77(B)
FY+3(+12.3%)$17.70(B)
FY+4(+8.2%)$19.15(B)
FY+5(+10.5%)$21.16(B)

EPS

CAGR: 10.9%
FY+1FY+2FY+3FY+4FY+5
FY+1$4.55
FY+2(+13.8%)$5.18
FY+3(+11.4%)$5.77
FY+4(+6.1%)$6.12
FY+5(+12.5%)$6.89

FCF per share

CAGR: 12.6%
FY+1FY+2FY+3FY+4FY+5
FY+1$5.22
FY+2(+10.5%)$5.76
FY+3(+14.2%)$6.58
FY+4(+2.6%)$6.75
FY+5(+24.2%)$8.39

Historical Financials

Showing limited histrical data. Access 10+ years of financials now! Upgrade
YearlyQuarterly
Income
FY2005FY2006FY2007FY2008FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
FY2005FY2006FY2007FY2008FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024TTM5Y avg5Y CAGR
Revenue26.62(B)37.42(B)44.35(B)45.81(B)54.07(B)54.98(B)41.65(B)19%
COGS5.30(B)12.44(B)12.39(B)8.27(B)10.21(B)10.23(B)9.72(B)18%
Gross Profit21.32(B)24.98(B)31.96(B)37.54(B)43.87(B)44.75(B)31.93(B)20%
Total OpEx.17.40(B)25.12(B)27.45(B)28.82(B)33.62(B)34.19(B)26.48(B)18%
  R&D5.99(B)9.74(B)9.76(B)10.94(B)13.58(B)13.96(B)10.00(B)23%
  SG&A11.90(B)15.59(B)17.98(B)18.22(B)20.22(B)20.53(B)16.78(B)14%
Operating Income3.92(B)-139.00(M)4.51(B)8.72(B)10.25(B)10.56(B)5.45(B)27%
Interest Expense-1.27(B)-1.28(B)-1.33(B)-1.59(B)-1.68(B)-1.68(B)-1.43(B)7%
Interest Income83.00(M)43.00(M)81.00(M)301.00(M)345.00(M)431.00(M)170.60(M)43%
Pre-tax income3.92(B)-265.00(M)2.50(B)6.90(B)8.69(B)9.29(B)4.35(B)22%
Income tax-772.00(M)380.00(M)792.00(M)-938.00(M)-1.65(B)-1.51(B)-437.60(M)21%
Net Income3.20(B)112.00(M)3.29(B)5.96(B)7.04(B)7.77(B)3.92(B)22%
Cash flow
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Stock-based Comp.FCFCFONet IncomeD&ACFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
EPS (Basic)FCF/ShareDividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
P/EP/SEV/EarningsP/FCFP/BEV/FCFDebt/EquityPayout ratio
Margins
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
ROICROAROCEROE
Shares outstanding
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Shares (Basic)Shares (Diluted)
Market Cap.
FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Market Cap.

Similar Companies

Ownership

Major holders

Insiders: 0.00%
Institutions: 17.06%
Other: 82.93%

Institutional ownership

2.18% Price (T.Rowe) Associa...1.55% Primecap Management Co...1.36% Wellington Management ...1.21% Bank of America Corpor...1.19% Capital International ...0.88% FMR, LLC0.80% Franklin Resources, In...0.77% Fisher Asset Managemen...0.60% Morgan Stanley0.57% Sanders Capital, LLC5.95% Others

Insider transactions

Show:
Buys
Sells
Grants
DateSharesTotal ($)Price ($)NameTitle
Buy2025-04-301,400100,32471.7Knudsen (Karen)
Buy2024-11-193,000190,20063.4Mok (Tony)

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Summary